Risk factors for acute rejection in renal transplant recipients experiencing delayed graft function

Clinical Transplantation

Volumn 22, Issue 5, 2008, Pages 634-638

  Moore, Jason ^a   Tan, Kay ^a   Cockwell, Paul ^a   Krishnan, Hari ^a   Mcpake, Dawn ^a   Ready, Andrew ^a   Mellor, Steve ^a   Hamsho, Ahmed ^a   Ball, Simon ^a   Lipkin, Graham ^a   Borrows, Richard ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Acute rejection; Delayed graft function; Renal transplant

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; HLA DR ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DIALYSIS; DRUG USE; FEMALE; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; CALCINEURIN; CASE-CONTROL STUDIES; COMPLEMENT C2; DELAYED GRAFT FUNCTION; FEMALE; GRAFT REJECTION; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; ROC CURVE;

EID: 52649160269     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00837.x     Document Type: Article

References (34)

1. Feldman HI, Gayner R, Berlin JA et al. Delayed function reduces renal allograft survival independent of acute rejection. Nephrol Dial Transplant 1996: 11: 1306.
2. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998: 66: 1697.
3. Moreso F, Seron D, Gil-Vernet S et al. Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients. Nephrol Dial Transplant 1999: 14: 930.
4. Matas AJ, Gillingham BJ, Elick BA et al. Risk factors for prolonged hospitalization after kidney transplants. Clin Transplant 1997: 11: 259.
5. Rosenthal JT, Danovitch GM, Wilkinson A, Ettenger RB. The high cost of delayed graft function in cadaveric renal transplantation. Transplantation 1991: 51: 1115.
6. T roppmann C, G illingham KJ, B enedetti E et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation 1995: 59: 962.
7. Lebranchu Y, Halimi JM, Bock A et al. Delayed graft function: Risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study. Transplant Proc 2005: 37: 345.
8. Qureshi F, Rabb H, Kasiske BL. Silent acute rejection during prolonged delayed graft function reduces kidney allograft survival. Transplantation 2002: 74: 1400.
9. Benvenisty AI, Cohen D, Stegasll MD, Hardy MA. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Transplantation 1990: 49: 321.
10. McTaggart RA, Tomlanovivh S, Bostrom A, Roberts JP, Feng S. Comparison of outcomes after delayed graft function: Sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimes. Transplantation 2004: 78: 475.
11. Gaber LW, Gaber AO, Hathaway DK, Vera SR, Shokouh-Amiri MH. Routine early biopsy of allografts with delayed graft function: Correlation of histopathology and transplant outcome. Clin Transplantation 1996: 10: 629.
12. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
13. Shapiro R, Randhawa P, Jordan ML et al. An analysis of early renal transplant protocol biopsies - the high incidence of subclinical tubulitis. Am J Transplant 2001: 1: 47.
14. Furness P, Taub N. International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP Project. Kidney Int 2001: 60: 1998.
15. Clase CM, Mahalati K, Kiberd BA et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. Am J Transplant 2002: 2: 789.
16. International Neoral Renal Transplantation Study Group. Randomized, International Study of Cyclosporine Microemulsion Absorption Profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002: 2: 157.
17. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neural) during the first 2weeks after renal transplantation. Transplantation 2001: 72: 1024.
18. Birsan T, Loinig C, Bodingbauer M et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: Retrospective analysis of a single-center experience. Transplantation 2004: 78: 1787.
19. Kyllonen LE, Salmela KT. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: A prospective randomized single-center pilot study. Transplantation 2006: 81: 1010.
20. Perico N, Ruggenenti P, Gotti E et al. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. trial. Kidney Int 2004: 65: 1084.
21. Einecke G, Schutz M, Mai I et al. Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 2005: 20: 1463.
22. Jain S, Curwood V, White SA, Furness P, Nicholson ML. Sub-clinical acute rejection detected using protocol biopsies in patients with delayed graft function. Transpl Int 2000: 13(Suppl. 1): S52.
23. Budde K, Bosmans J-L, Sennesael J et al. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. Clin Nephrol 2007: 3: 164.
24. Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ. Timing of cyclosporine administration in patients with delayed graft function. J Surg Res 1987: 43: 489.
25. Michael HJ, Francos GC, Burke JF et al. A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation 1989: 48: 805.
26. Kasiske BL, Johnson HJ, Goerdt PJ et al. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients. Am J Kidney Dis 1997: 30: 639.
27. de Sévaux RG, Smak Gregoor PJ, Hené RJ et al. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. J Am Soc Nephrol 2001: 12: 1750.
28. Kamar N, Garrigue V, Karras A et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: A randomized, multicenter study. Am J Transplant 2006: 6: 1042.
29. Charpentier B, Rostaing L, Berthoux F et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003: 75: 844.
30. Mourad G, Garrigue V, Squifflet J-P et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001: 72: 1050.
31. Cho S, Hodge E, Navarro M. Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. Transplant Proc 1999: 31: 322.
32. Kaplan B, Meier-Kriesche HU, Friedman G et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999: 39: 715.
33. Borrows R, Chusney G, Loucaidou M et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: Association with acute rejection and toxicity. Am J Transplant 2006: 6: 121.
34. Kouwenhoven EA, de Bruin RW, Bajema IM, Marquet RL, Ijzermans JN. Cold ischemia augments allogeneic-mediated injury in rat kidney allografts. Kidney Int 2001: 59: 1142.